Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859221 · ClinicalTrials.gov registry record · NA
Radiotherapy for Oligometastatic Prostate Cancer
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT01859221 is a NA study that has completed, run by University of Florida. The registered enrollment target is 39 participants.
The verdict
NCT01859221, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.
Interventions
- RADIATION Stereotactic radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-05 |
| Est. Completion | 2022-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859221
The ClinicalTrials.gov registry entry for NCT01859221 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic radiation is the first listed.
NCT01859221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859221 about?
NCT01859221 is a clinical study titled "Radiotherapy for Oligometastatic Prostate Cancer". The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.
What is the current status of trial NCT01859221?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2013-05. Estimated completion is 2022-09-13.
What interventions are being tested in trial NCT01859221?
The interventions under investigation include: Stereotactic radiation (RADIATION).
Who is sponsoring clinical trial NCT01859221?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.